IMEXHS Wins Major Public Tender in Mexico for Aquila+ Platform

Why It Matters

The deal validates IMEXHS’s ability to secure large public‑sector contracts and accelerates recurring revenue growth, positioning the company for stronger profitability and market share in AI‑driven radiology services.

Key Takeaways

• Mexico tender adds $384k ARR and $50k implementation fee.
• Deployment across 20 sites; full ARR run‑rate by Sep 2026.
• FY25 revenue up 9.5% to $29 M; EBITDA $1.6 M.
• 27 partners in 12 countries generate 60% of Q1 FY26 software ARR.
• One customer contributed ~33% of external revenue in FY25.

Pulse Analysis

The Mexican public tender marks a strategic foothold for IMEXHS in a market eager for AI‑enhanced diagnostic tools. By embedding five proprietary AI workflow agents and two Gleamer algorithms into Aquila+, the company offers a comprehensive solution that can streamline scheduling, image analysis, and report generation. Such capabilities are increasingly demanded by public health systems seeking efficiency gains and cost reductions, making the $384,000 ARR contract a bellwether for future government contracts across Latin America.

IMEXHS’s FY25 financials illustrate a decisive turnaround. Revenue climbed to $29 million, driven by a 16% surge in ARR to $34.8 million, while underlying EBITDA more than tripled to $1.6 million. The balance sheet also improved, with cash rising to $3.3 million and debt trimmed to $0.5 million. These metrics signal that the company’s AI platform and service model are beginning to translate into sustainable profitability, reducing reliance on one‑off hardware sales.

Growth now hinges on scaling the partner ecosystem and executing the Mexico rollout without delay. With 27 active partners across 12 countries contributing 60% of Q1 FY26 software ARR, channel expansion is a proven revenue engine. However, concentration risk—one client accounted for a third of FY25 external revenue—and operational challenges in markets like Colombia pose execution hurdles. Successful implementation by June 2026 and achieving the full ARR run‑rate by September will be critical milestones that investors will watch closely.